Skip to main content
. Author manuscript; available in PMC: 2009 Sep 17.
Published in final edited form as: Gynecol Oncol. 2008 Mar 14;109(2):168–173. doi: 10.1016/j.ygyno.2008.01.012

Figure 2.

Figure 2

Graphic depiction (from left to right) of the distribution of p53 signatures in tubes from BRCA+ women, consecutive women untested for BRCA or negative for ovarian cancer from a prior study (right),14, BRCA+ OSE, and BRCA+ ovarian CICs.